Details checkedClinical trial listing onlyCheckedregistry

Vanderbilt Donepezil Study in Cochlear Implant Users

Also known as: Donepezil, Aricept, Effect of Donepezil on Speech Recognition in Cochlear Implant Users, NCT05438264

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Early Phase 1

Status

Active

Target Gene

—

Route / Mode

Oral

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, bilateral, sensorineural, cochlear-implant

Trial IDs

Mechanism

Active-not-recruiting early Phase 1 study evaluating daily donepezil 5 mg versus placebo for speech recognition in cochlear implant users with bilateral sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Verified as an institution-led study of a generic repurposed small molecule in cochlear implant users, not a commercial donepezil hearing-loss pipeline program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT05438264

Open

Key Events

2023-03-10

Registry lists actual start for donepezil speech-recognition study in cochlear implant users

Clinical Trials (1)

NCT05438264

Data Checks